-+ 0.00%
-+ 0.00%
-+ 0.00%

Aptevo Reports 93% Clinical Benefit Rate With Mipletamig Triplet in Evaluable Frontline Acute Myeloid Keukemia Patients With TP53 Mutations

Benzinga·09/03/2026 12:10:27
Listen to the news

Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success